Global Blood Therapeutics
Income Statement

Last updated:

Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Global Blood Therapeutics's past years’ income statements indicate that its last revenue has increased compared to the previous period by 57% to $194,749,000. Profit margin reached -156%. Total operating expenses were $479,123,000.

Profit Margin

Global Blood Therapeutics, Inc. (NASDAQ:GBT): Profit margin
2013 0 -18.11M
2014 0 -20.80M
2015 0 -46.36M
2016 0 -82.46M
2017 0 -117.02M
2018 0 -174.19M
2019 2.10M -266.76M -12654.93%
2020 123.80M -247.55M -199.96%
2021 194.74M -303.09M -155.63%

GBT Income Statement (2013 – 2021)

2021 2020 2019 2018 2017 2016 2015 2014 2013
Revenue
Revenue
194.74M123.80M2.10M000000
Cost of revenue
3.31M1.98M48K000000
Gross profit
191.43M121.81M2.06M000000
Operating exp.
Research and development
212.13M155.12M174.55M131.30M87.80M61.21M36.65M16.32M12.85M
Selling and marketing
000000000
Total operating expenses
479.12M365.97M291.64M182.74M119.24M83.12M46.39M20.17M15.16M
Operating income
-287.14M-243.17M-281.28M-182.74M-119.24M-83.12M-46.39M-20.51M-15.66M
Other income (expenses), net
-15.46M-4.38M14.51M8.54M2.22M659K33K-296K-2.45M
Income before tax
-302.61M-247.55M-266.76M-174.19M-117.02M-82.46M-46.36M-20.80M-18.11M
Income tax expense
477K5.42M14.51M8.54M2.22M659K33K-296K-2.45M
Net income
-303.09M-247.55M-266.76M-174.19M-117.02M-82.46M-46.36M-20.80M-18.11M
Earnings per share
Basic EPS
-4.82-4.04-4.57-3.41-2.76-2.48-3.62-1.51-0.83
Diluted EPS
-4.82-4.04-4.57-3.41-2.76-2.48-3.62-1.51-0.83
Data sourceData sourceData sourceData sourceData sourceData sourceData source